ASHP
  • Program
  • Registration
  • ASHP Spotlight
  • Midyear Coverage
  • Awards and Events
  • ASHP Marketplace
  • Meeting Info
  • Previews
Topics
  • ASHP Spotlight
  • Midyear Coverage
  • Awards and Events
  • ASHP Marketplace
  • Meeting Info
  • Previews
Resources
  • Program
  • Registration
Facebook iconTwitter iconLinkedIn iconInstagram icon
October 27, 2021

Physician and Pharmacist Experts Explore the New C. difficile Guidelines


From left: Carolyn D. Alonso and Travis Carlson
From left: Carolyn D. Alonso and Travis Carlson

Clostridioides difficile infection (CDI) is the most common healthcare-associated infection and the most common cause of mortality in patients with gastroenteritis in the United States. Historically, approximately one in four patients suffer from recurrent CDI, which is associated with increased morbidity, mortality, healthcare costs, and decreased quality of life. Recent updates to national guidelines place a greater emphasis on recurrence prevention. This symposium explores these guideline updates.

Join us for this Virtual Midday Symposium where Travis Carlson, assistant professor of clinical sciences, Fred Wilson School of Pharmacy, High Point University, High Point, North Carolina and Carolyn D Alonso, assistant professor of medicine, Harvard Medical School, Boston, Massachusetts, will examine recent data on CDI pharmacotherapy and use a case-based approach to apply recent guideline recommendations to special patient populations, with a focus on those at high risk for recurrent CDI.

CDI is a consequence of disruption of the indigenous gut microbiota by antibiotics, which creates an environment within the intestine that promotes C. difficile spore germination, vegetative growth, and toxin production, leading to epithelial damage and colitis. CDI is associated with life-threatening complications, including pseudomembranous colitis, toxic megacolon, perforations of the colon, and sepsis.  Given the unacceptably high morbidity and economic impact of recurrent CDI, education for clinicians on its etiology, prevention, and treatment is essential. CDI is considered an urgent threat by the Centers for Disease Control and Prevention and many clinicians do not fully understand the complexity of CDI and its treatment, specifically how the use of broad-spectrum antibiotics can increase the risk of CDI and its recurrence. Incorporating these latest evidence-based guidelines into practice requires the attention and effort of the entire interprofessional team, including those responsible for antibiotic stewardship.

Learners will take away strategies to develop interprofessional, cost-effective treatment plans that optimize therapy and provide rational anti-CDI recurrence treatment.

This 1.5-hour virtual Midday Symposium, Applying the Guidelines on Recurrent Clostridioides difficile Infection in Special Patient Populations takes place on Monday, Dec. 6 from 1 to 2:30 p.m. ET, and is accredited for both continuing medical and pharmacy education. Register now at www.ashpadvantage.com/cdiffupdate and explore the full initiative which includes podcasts, live and enduring webinars, and faculty commentaries.

This activity is provided by ASHP and supported by an educational grant from Merck.

Featured Stories
Geospatial Tools Offer Fresh Perspective on Patient Care
Sponsored by ASHP
Geospatial Tools Offer Fresh Perspective on Patient Care
ASHP announces new Leadership Center and Membership Group
Sponsored by ASHP
ASHP announces new Leadership Center and Membership Group
More Content
Close Up Hand Holding Covid 19 Vaccine 2021 08 28 03 48 08 Utc
ASHP Midyear 2021
FDA, CDC Experts Share COVID-19 Vaccine Progress
December 8, 2021
Thomas Lodise and Michael Rybak
ASHP Midyear 2021
Trough Levels Don’t Cut It for Vancomycin Dosing in Seriously Ill Patients
December 8, 2021
Getty Images 1344197992
ASHP Midyear 2021
Anti-Racism and Its Role in Achieving Health Equity
December 8, 2021
Getty Images 638044582
ASHP Midyear 2021
Don’t Get Caught Sleeping on 340B, Experts Say
December 8, 2021
Cyrine Haidar and Shannon Manzi
ASHP Midyear 2021
Pharmacogenomic Testing Can Benefit Children and Families
December 8, 2021
Brenda Jensen and Jerald Ovesen
ASHP Midyear 2021
Big Changes Coming From USP and NIOSH
December 8, 2021
Tyler Vest
ASHP Midyear 2021
New Research Brings Changes to the Medication-Use Process
December 8, 2021
Terri Jorgenson and Lisa Kearney
ASHP Midyear 2021
An All Hands on Deck Approach for Mental Health and Pain Care
December 8, 2021
Cheyenne Frazier and Karen Gunning
ASHP Midyear 2021
Transgender Care Is Patient Care
December 8, 2021
From left: Andre D. Harvin, Patricia C. Kienle, and Clinton L. Meachum
ASHP Midyear 2021
Thursday’s Virtual Midday Symposia
December 8, 2021
Getty Images 1313783716
ASHP Midyear 2021
Highlights from 10th Annual Pharmacy Forecast Unveiled at Midyear
December 7, 2021
Jao Tribute Mdn
ASHP Midyear 2021
Remembering Joseph A. Oddis, a Giant in Pharmacy
December 7, 2021
ASHP
Facebook iconTwitter iconLinkedIn iconInstagram icon
© 2023 Ascend Media. All rights reserved.